Metrics as of 10/15/2026, 01:19 AM (Berlin time), refresh in progress.
Anixa Biosciences Stock
Anixa Biosciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Amit Kumar
- Employees
- 4
- Market cap
- $92 M
- IPO
- 07/10/1983
Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel…
Anixa Biosciences stock: price history
1D
-0.4%
1W
-9.8%
1M
-5.0%
6M
-9.2%
YTD
-14.7%
1Y
-38.6%
2Y
-12.8%
5Y
-39.4%
10Y
-52.5%
Next earnings date
Next earnings date
11/01/2027 (in 86 days)
Volatility around earnings
~23% weaker price swings than usual
Ask the agents about Anixa Biosciences
Analyst assessment of Anixa Biosciences
PRICE TARGET LOW
US$6.00
CONSENSUS
US$6.00
MEDIAN
US$6.00
PRICE TARGET HIGH
US$6.00
0
STRONG BUY
6
BUY
0
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 22/09/2026
Anixa Biosciences stock metrics
P/E
-8.7
P/B
6.27
EV/EBITDA
-8.63
RETURN ON EQUITY
-18.0%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
31/07/2026
Free float & liquidity
FREE FLOAT
94.3%
FLOAT SHARES
32,767,002
AVG. DAILY VOLUME (30D)
342,539
Insider transactions (SEC)
Catelani Michael
KUMAR AMIT
Baskies Arnold M
Titterton Lewis H jr
Titterton Lewis H jr
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Anixa Biosciences stock
What does Anixa Biosciences do?
Anixa Biosciences, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Amit Kumar, the company employs around 4 people.
The IPO was on 07/10/1983; the stock trades on NASDAQ under the ticker ANIX.
What do analysts say about Anixa Biosciences stock?
6 analysts rate the stock, the consensus is Buy (as of 22/09/2026).
The average price target is US$6.00, ranging from US$6.00 to US$6.00, with a median of US$6.00.
This is an external assessment, not a statement by Market Jury.
When does Anixa Biosciences report next?
The next earnings date is 11/01/2027.
Around past earnings, price swings were roughly -23% stronger than usual.
Does Anixa Biosciences pay a dividend?
No, Anixa Biosciences currently does not pay a dividend.
Which stocks are comparable to Anixa Biosciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Anixa Biosciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Anixa Biosciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.